GO
Loading...

Enter multiple symbols separated by commas

Gilead Sciences Inc

More

  • BOSTON, March 25- CEOs at large U.S. companies collectively realized at least $6 billion more in compensation than initially estimated in annual disclosures in the five years after the financial crisis first hit, according to a Reuters analysis. About 300 CEOs who served throughout the 2009-2013 period at S&P 500 companies together realized about $22 billion...

  • Biotech done? And an under-the-radar top stock Tuesday, 24 Mar 2015 | 12:27 PM ET
    Harvoni

    In his latest "New Ideas" column for CNBC Pro, Brian Sullivan discusses the dollar-oil link, a biotech bubble and the hottest stock of the year.

  • *Dollar dips but oversupply worry weighs on oil. NEW YORK, March 23- U.S. stocks were little changed on Monday on the heels of a rally in the prior week, as investors weighed fluctuations in the dollar and its impact on other markets, including crude prices. The Nasdaq was less than 0.5 percent of a closing record set on March 10, 2000.

  • US STOCKS-Wall St little changed as energy pares gains Monday, 23 Mar 2015 | 12:29 PM ET

    *Dollar weakens, supporting crude prices. NEW YORK, March 23- U.S. stocks were little changed on Monday, following strong gains in major indexes the previous week, as investors assessed gyrations in the dollar and crude prices and their impact on equities. "The market has been in a back-and-forth motion for the last couple of weeks, caught between the potential for...

  • US STOCKS-Stocks up as dollar ads to losses, oil gains Monday, 23 Mar 2015 | 10:06 AM ET

    *U.S. dollar extends losses, crude turns positive. NEW YORK, March 23- U.S. stocks edged higher on Monday following strong gains in major indexes the previous week, as investors assessed gyrations in the dollar and crude prices and their impact on equities. "The market has been in a back-and-forth motion for the last couple of weeks, caught between the potential for...

  • *Brent, WTI prices fall again after Saudi comment on supply. NEW YORK, March 23- U.S. stocks were set to dip at the open on Monday following strong gains in major indexes the previous week, as investors assessed gyrations in the dollar and crude prices and their impact on equities. "The market has been in a back and forth motion for the last couple of weeks, caught between...

  • NEW YORK, March 23- U.S. stock index futures ticked lower on Monday following strong gains in major indexes last week, as investors eyed negotiations over the future of Greece in the euro zone and as oil prices fell further. *German Chancellor Angela Merkel and Greek Prime Minister Alexis Tsipras were set to meet in Berlin, and Tsipras' list of reform proposals will...

  • Lightning Round: Too much competition in this Friday, 20 Mar 2015 | 7:44 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: Cha-ching! Time to cash in Friday, 20 Mar 2015 | 7:26 PM ET
    Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer on why this rally won’t last forever and why you should take some off the table on this.

  • 6 trades on surging biotech sector Friday, 20 Mar 2015 | 6:39 PM ET

    Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.

  • These stocks are insulated from the rising dollar Friday, 20 Mar 2015 | 4:21 PM ET
    Biotech

    Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.

  • Workers at 11 companies haul in $3.5M each! Friday, 20 Mar 2015 | 8:57 AM ET
    Workers enter an Exxon Mobil refinery

    Employees at 11 non-financial companies in the Standard & Poor's 500 brought in more revenue apiece than any other in America. USA TODAY reports.

  • Charity attacks Gilead over hepatitis C drug restrictions Wednesday, 18 Mar 2015 | 4:17 PM ET

    March 18- Charity Medecins Sans Frontieres has accused U.S. drugmaker Gilead Sciences Inc of restricting access to its breakthrough hepatitis C drug Sovaldi in developing countries as it tries to protect profit margin in wealthier nations. "We're seeing Gilead trying everything it can to squeeze every last drop of profit out of some middle-income and...

  • Early movers: DSW, BABA, EBAY, RTN, AAPL & more Tuesday, 17 Mar 2015 | 7:56 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • The widespread use of a combination of drugs that include Gilead Sciences Inc's Sovaldi, known generically as sofosbuvir, will nonetheless be a significant cost for the U.S. healthcare system, researchers wrote. Sovaldi's initial $84,000 price drew widespread criticism last year, and insurers have since pressed Gilead and rival AbbVie Inc to offer steep...

  • Top stock picker fleeing strong dollar Monday, 16 Mar 2015 | 7:00 AM ET
    Pedestrians walk by a CVS store in San Francisco.

    Louis Navellier's Squawk Box Platinum Portfolio is already up 20 percent this year. Here's his next move.

  • NEW YORK, March 15- As drugmakers develop new medicines to battle a liver disease epidemic, they have created an urgent need for better diagnostics to select patients for treatment and assess their drugs' effectiveness. About 30 percent of people in the U.S. now suffer from fatty liver diseases, such as NASH, fueled by obesity, diabetes and over-indulgent...

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...

  • What!?! Specialty drug spending jumps 31% Tuesday, 10 Mar 2015 | 8:53 AM ET
    Prescription drugs

    Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.